1、2025 Global biotech sector surveySurvey reportHow ambiguity is shaping biotech ambition22025 Global biotech sector surveyContentsForeword 03Executive summary 04Key findings 05Introduction 06Funding challenges:More money for the lucky few 08Alternative funding models 11Organisation pipeline 12Small m

2、olecules get smaller 12Therapeutic area activity 14Neurology overtakes oncology 14The patent cliff and biosimilars 17Untapped opportunities on the horizon 17 Case study:Oncology biosimilars 17China:Threat,opportunity or catalyst?18Macro environment 20Business as usual when uncertainty is the only ce

3、rtainty 20The talent shortage paradox and drug development complexity 22AI,digital tools and innovation in clinical trials 26From futuristic hype to everyday reality 26Conclusion 29References 30Acknowledgements 31Further reading 32Appendix:Full survey results 3432025 Global biotech sector surveyFore

4、word“A career in biotech is not for the fainthearted.It demands the resolve to overcome challenges that happen within the laboratory and to weather the impact of changes imposed by the wider world.Our 2025 survey results show that biotechs are rising to the many challenges they face with optimism an

5、d determination.Funding is always top of mind for biotechs,particularly smaller and midsize organisations.It remains one of the biggest challenges biotechs face,with the record deals and financing of the early 2020s now a distant memory.Drug development is complex and expensive,with no guarantees th

6、at a molecule will successfully reach the marketplace.Technology and AI tools can help resource-constrained biotechs throughout the drug development life cycle by supporting day-to-day functionality and freeing people to focus on strategy and innovation.Our survey shows that most biotechs expect AI